Korrektion – årsrapport 2022 med zip fil
Korrektion – årsrapport 2022 med zip fil.
Vedhæftet fil
For at se dette indhold fra www.globenewswire.com, så skal du give din accept på toppen af denne side.For at se dette indhold fra ml-eu.globenewswire.com, så skal du give din accept på toppen af denne side.
Information om GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg pressemeddelelser fra GlobeNewswire by notified
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra GlobeNewswire by notified
Notification and Public Disclosure of Transactions by Persons Discharging Managerial Responsibilities21.3.2023 16:00:00 CET | Press release
Company Announcement No. 16/2023 Copenhagen, 21 March 2023 Notification and Public Disclosure of Transactions by Persons Discharging Managerial Responsibilities 1. Information on the person discharging managerial responsibilities/person closely associated a) Name Niels Frederiksen 2. Reason for the notification a) Position/title CEO and member of the Executive Management b) Initial notification/amendment Initial notification 3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name Scandinavian Tobacco Group A/S b) LEI code 5299003KG4JS99TRML67 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument, type of instrument Identification code Shares DK0060696300 – STG b) Nature of the transaction Grant of shares due to vesting of performance share
Sandoz receives US FDA approval for biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation21.3.2023 15:48:10 CET | Press release
Biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation (HCF) approved for seven indications of reference medicine Humira®* With this approval, Sandoz adalimumab HCF biosimilar will offer US patients reduced injection volume in citrate-free formulation Sandoz continues to expand patient access to much-needed medications, increase healthcare savings and fuel innovation through increased competition Basel, March 21, 2023 – Sandoz, a global leader in generic pharmaceuticals and biosimilars, today announced that the US Food and Drug Administration (FDA) approved a citrate-free high-concentration formulation (HCF) of its biosimilar Hyrimoz® (adalimumab-adaz) injection. The adalimumab citrate-free HCF (100 mg/mL) is approved to treat seven indications covered by the reference medicine, Humira®* (adalimumab), including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis and plaque psoriasis.1 Sandoz
Articles of Association for RTX A/S21.3.2023 15:28:54 CET | Press release
Nørresundby, Denmark, 21 March 2023 Announcement no. 11/2023 Articles of Association for RTX A/S as adopted at the Annual General Meeting on 26 January 2023 and finally adopted at the extraordinary general meeting on 10 March 2023 (cf. company announcement 10/2023) has been registered and published. The Articles of Association are available at the company’s website www.rtx.dk under: Governance => Articles of Association. Questions and further information: CEO Peter Røpke, tel: +45 96 32 23 00 Attachment RTX A-S - Articles of Association 10 March 2023
Vedtægter for RTX A/S21.3.2023 15:28:54 CET | pressemeddelelse
Nørresundby, den 21. marts 2023 Selskabsmeddelelse nr. 11/2023 Vedtægter for RTX A/S som vedtaget på RTX’s ordinære generalforsamling 26. januar 2023 og endeligt vedtaget på selskabets ekstraordinære generalforsamling 10. marts 2023 (jf. selskabsmeddelelse 10/2023) er blevet registreret og offentliggjort. Vedtægterne er tilgængelige på selskabets hjemmeside www.rtx.dk under: Governance => Vedtægter. Spørgsmål og yderligere oplysninger: CEO Peter Røpke, tlf: +45 96 32 23 00. Vedhæftet fil RTX A-S - vedtægter pr. 10. marts 2023
PARKEN Sport & Entertainment A/S - Bestyrelsesændring21.3.2023 15:24:14 CET | pressemeddelelse
William Kvist genopstiller ikke til bestyrelsen på selskabets ordinære generalforsamling den 21. april 2023. William Kvist har været en del af bestyrelsen siden 2019 og var i en periode også fungerende sportslig leder i F.C. København. Vedhæftet fil 09-2023 Bestyrelsesændring